🇺🇸 FDA
Pipeline program

Mometasonfuroaat Teva 50 microgram/verstuiving, neusspray, suspensie, Mometasonfuroat-ratiopharm® 50 Mikrogramm/Sprühstoß Nasenspray, Suspension, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection., Fasenra 30 mg solution for injection in pre-filled syringe

D3252C00002

Phase 3 small_molecule active

Quick answer

Mometasonfuroaat Teva 50 microgram/verstuiving, neusspray, suspensie, Mometasonfuroat-ratiopharm® 50 Mikrogramm/Sprühstoß Nasenspray, Suspension, Placebo for benralizumab for clinical trials is a sterile liquid solution presented in an accessorized prefilled syringe (apfs) for subcutaneous injection., Fasenra 30 mg solution for injection in pre-filled syringe for Severe CRSwNP patients with asthma. is a Phase 3 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Severe CRSwNP patients with asthma.
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials